
Beacon Biosignals is an AI-driven neurotechnology company focused on accelerating drug development for neurological and psychiatric conditions. Their end-to-end platform utilizes FDA-cleared EEG…

Beacon Biosignals is an AI-driven neurotechnology company focused on accelerating drug development for neurological and psychiatric conditions. Their end-to-end platform utilizes FDA-cleared EEG…
What they do: AI-driven neurotechnology: FDA-cleared EEG headbands, cloud datastore, and analytics for biomarkers and clinical-trial support
Founded: 2019
Headquarters: Boston (evidence indicates Boston-based)
Recent financing: Series B upsized to over $97M; cumulative funding reported >$132M
Neurological, psychiatric, and sleep disorders; translational research and clinical-trial biomarker development
2019
Software Development
$86,000,000
Announced $86M Series B (later upsized)
over $97,000,000
Upsized Series B bringing the round to over $97M and cumulative funding to over $132M
General Catalyst listed as lead investor on an earlier round (Series A referenced in records)
“Syndicate includes Innoviva, GV (Google Ventures), S32 (Sanofi Ventures), Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital, and others”
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
81,000+
Open Roles
4,600+
New This Week
| Company |
|---|